Calithera Biosciences (NASDAQ:CALA) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Calithera Biosciences (NASDAQ:CALAFree Report) in a report released on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Calithera Biosciences Stock Performance

Shares of NASDAQ:CALA opened at $0.02 on Tuesday. Calithera Biosciences has a 12-month low of $0.01 and a 12-month high of $0.50. The company’s 50 day moving average price is $0.03 and its two-hundred day moving average price is $0.04.

Hedge Funds Weigh In On Calithera Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. bought a new position in Calithera Biosciences in the first quarter valued at approximately $404,000. Affinity Asset Advisors LLC acquired a new stake in shares of Calithera Biosciences in the 1st quarter valued at $404,000. Renaissance Technologies LLC increased its stake in shares of Calithera Biosciences by 36.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company’s stock valued at $749,000 after purchasing an additional 496,100 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Calithera Biosciences by 143.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock worth $50,000 after buying an additional 72,865 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Calithera Biosciences by 23.4% during the 3rd quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock worth $415,000 after buying an additional 26,800 shares during the last quarter. Institutional investors own 0.02% of the company’s stock.

About Calithera Biosciences

(Get Free Report)

Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.

Read More

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.